Rodin Therapeutics is discovering and developing first in class therapeutics for cognitive disorders, applying unique insights into the role of epigenetics and best in class structural biology capabilities. Applying Rodin\'s unique access to the Proteros structural biology platform and deep experience in CNS drug development, the company has identified high potential targets and novel chemical strategies to address high unmet clinical needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/29/14 | $12,900,000 | Series A |
Atlas Venture Johnson & Johnson Innovation | undisclosed |
| 09/18/17 | $27,000,000 |
Atlas Venture Hatteras Venture Partners Remeditex Ventures Third Point Ventures | undisclosed |
